Journal Mobile Options
Table of Contents
Vol. 22, No. 1, 2003
Issue release date: January–February 2003
Neuroepidemiology 2003;22:13–22
(DOI:10.1159/000067109)

Risk Factors for Dementia in the Cardiovascular Health Cognition Study

Kuller L.H. · Lopez O.L. · Newman A. · Beauchamp N.J. · Burke G. · Dulberg C. · Fitzpatrick A. · Fried L. · Haan M.N.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The Cardiovascular Health Cognition Study has evaluated the determinants of dementia among 3,608 participants that had a magnetic resonance imaging (MRI) of the brain in 1991 and were followed to 1998–1999. Methods: There were 480 incident dementia cases, 330 (69%) were classified as Alzheimer’s disease (AD). Results: In univariate analysis, low scores on the Modified Mini-Mental State Examination (3MSE) and on the Digit Symbol Substitution Test as well as declines in scores over time prior to the development of dementia were significant predictors of dementia. A high ventricular grade on the MRI (atrophy) as well as high white matter grade, a number of brain infarcts on the MRI were all determinants of dementia. Apolipoprotein E ε4 (ApoE-4) was also a powerful predictor of dementia. In a multivariate Cox proportional hazards model controlling for race, gender and grade, the hazard ratios for age (1.1), 3MSE score (0.9), ventricular size (1.4), white matter grade (1.8), presence of large infarcts >3 mm (1.3) and ApoE-4 (2.1) were significant predictors of dementia. The combination of an ApoE-4 genotype, 3MSE score <90, ≧5 ventricular grade, ≧3 white matter grade at the time of the MRI were associated with a 17-fold increased risk (95% CI: 8.6–34.9) of dementia as compared to individuals with none of the above attributes. Conclusions: Measures of cognition, ApoE-4 and MRI of the brain are strong predictors of both dementia and of AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Khachaturian ZS, Mesulam MM (eds): Alzheimer’s disease: A compendium of current theories. Ann NY Acad Sci 2000, vol 924.
  2. Elias MF, Besier A, Wolfe P, Au R, White R, D’Agostino RB: The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham cohort. Arch Neurol 2000;57:808–813.
  3. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Bayeux R: Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 1994;271:1004–1010.
  4. Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, Merchant C, Lantigua R, Costa R, Stern Y, Mayeux R: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56:49–56.
  5. Growdon JH, Wurtman RJ, Corkin S, Nitsch RM (eds): The molecular basis of dementia. Ann NY Acad Sci 2000, vol 920.
  6. Yaffe K, Gregg EW: Diabetes mellitus, cognitive function, and risk of dementia in older adults. Harrisononline.com/ser...133/Updates/Editorials/ed12566.html (02–13–01).
  7. Hachinski V: Preventable senility: A call for action against the vascular dementias. Lancet 1992;340:645–648.
  8. Tatemichi TK, Desmond DW, Bayeux R, Paik M, Stern Y, Sano M, Remien RH, Williams JB, Mohr JP, Hauser WA: Dementia after stroke: Baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992;42:1185–1193.
  9. Schofield PW, Mosesson RE, Stern Y, Bayeux R: The age at onset of Alzheimer’s disease and an intracranial area measurement: A relationship. Arch Neurol 1995;52:95–98.
  10. Jobst KA, Smith AD, Szatmari M, Esiri MM, Jaskowski A, Hindley N, McDonald B, Molyneux AJ: Rapidly progressing atrophy of medial temporal lobe in Alzheimer’s disease. Lancet 1994;343:829–830.
  11. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS): Pathological correlates of late-onset dementia in a multicenter, community-based population in England and Wales. Lancet 2001;357:169–175.
  12. Kalaria RN, Ince P (eds): Vascular factors in Alzheimer’s Disease. Ann NY Acad Sci 2000, vol 903.
  13. Rogers J, Shen Y: A perspective on inflammation in Alzheimer’s disease. Ann NY Acad Sci 2000;924:132–135.
  14. Carney JM: Oxidative stress leading to loss of critical proteases in Alzheimer’s disease: An alternative view of the etiology of AD. Ann NY Acad Sci 2000;924:160–163.
  15. Myers RH, Schaefer EJ, Wilson PWF, D’Agostino R, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, McNulty KA, Beiser A, Wolf PA: Apolipoprotein E ε4 association with dementia in a population-based study: The Framingham Study. Neurology 1996;46:673–677.
  16. Selkoe DJ: The genetics and molecular pathology of Alzheimer’s disease: Roles of amyloid and the presenilins. Neurol Clin 2000;18:903–921.
  17. Manolio TA, Kronmal RA, Burke GL, Poirier V, O’Leary DH, Gardin JM, Fried LP, Steinberg EP, Bryan RN: Magnetic resonance abnormalities and cardiovascular disease in older adults. Stroke 1994;25:318–327.
  18. Bryan RN, Manolio TA, Schertz LD, Jungreis C, Poirier VC, Elster AD, Kronmal RA: A method for using MR to evaluate the effects of cardiovascular disease on the brain: The Cardiovascular Health Study. Am J Neuroradiol 1994;15:1625–1633.
  19. Bryan RN, Wells SW, Miller TJ, Elster AD, Jungreis CA, Poirier VC, Lind BK, Manolio TA: Infarct-like lesions in the brain: Prevalence and anatomic characteristics at MR imaging of the elderly – Data from the Cardiovascular Health Study. Radiology 1997;202:47–54.
  20. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR, for the Cardiovascular Health Study Collaborative Research Group: Lacunar infarcts defined by magnetic resonance imaging of 3,660 elderly people: The Cardiovascular Health Study. Arch Neurol 1998;55:1217–1225.
  21. Bernick CB, Kuller LH, Dulberg C, Longstreth WT, Manolio TA, Beauchamp NJ, Price TR: Infarction identified on brain MRI and risk of clinical stroke in the Cardiovascular Health Study. (Abstract 4147) Circulation 2000;102(suppl):II-864.
  22. Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, Burke GL, Tracy R , Bhadelia R: Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 1998;29:388–398.
  23. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L: The role of ApoE ε4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282:40–44.
  24. Yaffe K, Haan M, Byers A. Tangen C, Kuller L: Estrogen use, ApoE, and cognitive decline: Evidence of gene-environment interaction. Neurology 2000;54:1949–1953.
  25. Fried LP, Borhani NO, Enright P, Furberg CD, Garden JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A: The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1991;1:263–276.
  26. Radloff LS, Teri L: Use of the Center for Epidemiologic Studies depression scale with older adults. Clin Gerontol 1986;5:119–136.
  27. Sato R, Bryan RN, Fried LP: Neuroanatomic and functional correlates of depressed mood: The Cardiovascular Health Study. Am J Epidemiol 1999;150:919–929.
  28. Gallo JJ, Breitner JCS: Alzheimer’s disease in the NAS-NRC Registry of ageing twin veterans. IV. Performance characteristics of a two-stage telephone screening procedure for Alzheimer’s dementia. Psychol Med 1995;25:1211–1219.
  29. Jorm AF, Jacob PA: The informant questionnaire on cognitive decline in the elderly (IQ CODE): Socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015–1022.
  30. Newman AB, Gottdiener JS, McBurnie MA, Hirsch CH, Kop WJ, Tracy R, Walston JD, Fried LP, for the Cardiovascular Health Study Research Group: Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol 2001;56:M158–M166.
  31. Yue NC, Arnold AM, Longstreth WT Jr, Elster AD, Jungreis CA, O’Leary DH, Poirier VC, Bryan RN: Sulcal, ventricular, and white matter changes at MR imaging in the aging brain: Data from the Cardiovascular Health Study. Radiology 1997;202:33–39.
  32. Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N: Evaluations of dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology 2003;22:1–12.
  33. Lopez OL, Litvan I, Catt KE, Stowe R, Skunk W, Caffer DI, Becker JT, DeKosky ST: Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999;53:1992–1299.
  34. Cotman CW: Homoeostatic processes in brain aging: The role of apoptosis, inflammation, and oxidative stress in regulating healthy neural circuitry in the aging brain; in Stern PC, Carstensen LL (eds): The Aging Mind: Opportunities in Cognitive Research. Commission on Behavioral and Social Sciences and Education. Washington, National Academy Press, 2000, pp 114–143.
  35. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangelos EG, Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  36. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW: Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 2000;343:450–456.
  37. Fox NC, Crum WR, Cahill RI, Stevens JM, Jansen JC, Rossor MN: Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001;358:201–205.
  38. Longstreth WT Jr, Diehl P, Manolio TA, Beauchamp NJ, Jungreis CA, Lefkowitz D, for the Cardiovascular Health Study Collaborative Research Group: Cluster analysis and patterns of findings on cranial magnetic resonance imaging of the elderly. Arch Neurol 2001;58:635–640.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50